Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the biologic & biosimilar ra drugs market grown over the years?
There has been a hardy expansion in the size of the biologic & biosimilar ra drugs market over the recent years. The market, initially valued at $13.99 billion in 2024, is projected to increase to $14.71 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.2%. The surge during the historical period is linked to factors such as market adoption rates, results from clinical trials, alterations in market share, long-term patient results, and pricing tactics.
What Is the forecasted market size and growth rate for the biologic & biosimilar ra drugs market?
The market size for biologic and biosimilar ra drugs is projected to experience robust expansion in the upcoming years, with an estimated value of $19.51 billion by 2029, at a compound annual growth rate (CAGR) of 7.3%. The upswing during the forecast timeline is due to factors such as the escalation in biologic drug development, market rivalry, healthcare regulations, patient predilections, and clinical research and development. The forecast period also emphasizes noteworthy trends such as the augmentation in biosimilar market competition, customized medication and precision therapy, progress in drug delivery systems, emphasis on safety and effectiveness, and patient-oriented healthcare.
Get your biologic & biosimilar ra drugs market report here!
What are the major factors driving growth in the biologic & biosimilar ra drugs market?
The growth in the biologics and biosimilar RA drugs market is being propelled by the escalating elderly population and the increasing prevalence of rheumatoid arthritis. The term “older population” applies to individuals who are 60 years old or over. Rheumatoid arthritis is an autoimmune condition where a person’s immune system assaults its healthy cells, particularly affecting the individual’s joints. This disease is more common in the elderly as the immune system weakens with age. Biologics and biosimilar RA drugs are notably beneficial in the treatment of rheumatoid arthritis compared to traditional medication. For example, the World Health Organisation, a United Nations specialised health agency based in Switzerland, noted that there were about 1 billion individuals aged 60 and above globally in 2020. This population is predicted to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Additionally, the Centers for Disease Control and Prevention, a US governmental public health agency, forecasts the number of adults with arthritis in the US will reach 78.4 million by 2040, with potential activity limitations affecting 34.6 million due to arthritis-related conditions. Thus, the growing geriatric population in conjunction with an increase in RA cases is propelling the growth of the biologics and biosimilars RA drugs market.
What key areas define the segmentation of the global biologic & biosimilar ra drugs Market?
The biologic & biosimilar RA drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
What are the top market players propelling the growth of the biologic & biosimilar ra drugs industry?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
What are the key trends shaping the future of the biologic & biosimilar ra drugs market?
One significant trend in the biologic & biosimilar RA drugs market is the development of new innovations. To deliver cost-effective alternatives, major companies in this market are concentrating on creating biosimilar treatments such as Dual Concentration Biosimilar Options. In July 2023, for example, healthcare company Organon, based in the US, collaborated with biopharmaceutical company Samsung Bioepis from South Korea to release HADLIMA, a Humira (adalimumab) biosimilar, in the US. With low and high concentration options, HADLIMA enhances affordability and access for those suffering from autoimmune diseases. The product has an 85% discount to Humira’s price, helping increase patient accessibility. HADLIMA features an Arthritis Foundation-approved autoinjector and a patient support program, HADLIMA For You, that includes educational resources and co-pay assistance. Various conditions such as rheumatoid arthritis and Crohn’s disease can be treated with the biosimilar. HADLIMA comes in two versions: a citrate-free high concentration (100 mg/mL) and a citrate-infused low concentration (50 mg/mL) – both offering patients uninterrupted care continuity.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9255
What regions are dominating the biologic & biosimilar ra drugs market growth?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Dermatology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Hematology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report
Musculoskeletal Disorders Drugs Global Market Report 2022
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
